Related references
Note: Only part of the references are listed.Myelosuppression and kinase selectivity of multikinase angiogenesis inhibitors
R. Kumar et al.
BRITISH JOURNAL OF CANCER (2009)
Tyrosine Kinase Inhibitors - A Review on Pharmacology, Metabolism and Side Effects
Joerg Thomas Hartmann et al.
CURRENT DRUG METABOLISM (2009)
Pharmacogenetic Pathway Analysis for Determination of Sunitinib-Induced Toxicity
Nielka P. van Erp et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Toxicities associated with the administration of sorafenib, sunitinib, and temsirolimus and their management in patients with metastatic renal cell carcinoma
Naeem Bhojani et al.
EUROPEAN UROLOGY (2008)
Sunitinib versus interferon alfa in metastatic renal-cell carcinoma
Robert J. Motzer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial
George D. Demetri et al.
LANCET (2006)
Share Paper
